Salvarx Share Discussion Threads

[bobby.ifa] 13/5/2020 16:41

CSE, now 16%

[bscuit] 13/5/2020 16:02

OTC or CSE?

[bobby.ifa] 13/5/2020 15:17

Portage up 12.5%, 13-13.5p

[the stigologist] 03/5/2020 00:32

Uninvestable on pink sheets or CSE in my opinion

If they're going to list on Nasdaq get on on with it

[bscuit] 03/5/2020 00:27

CSE, though at present most action on OTC Pink in USA

[bobby.ifa] 19/4/2020 11:40

Are they listed on tradeable exchange?

[the stigologist] 19/4/2020 11:07

Interesting

[abadan2] 19/4/2020 10:51

Portage Biotech : provides update on portfolio company, Intensity Therapeutics, Inc.

0
04/15/2020 | 01:18pm BST
TORONTO, April 15, 2020 /PRNewswire/ - (PBT.U: CSE, PTGEF: OTC Markets) - Portage Biotech Inc. ("Portage" or the "Company") wishes to provide an update on a portfolio company, Intensity Therapeutics, Inc. ("Intensity"). Portage Biotech Inc. holds an 9.7% equity interest in Intensity.

Intensity signs clinical trial collaboration with Bristol Myers Squibb
Intensity's collaboration with Merck reports favorable safety of INT230-6 in combination with pembrolizumab
The company is launching seven phase 2 combination cohorts in solid tumors
Intensity Therapeutics announced yesterday it has entered into a clinical trial collaboration agreement with Bristol Myers Squibb Company (NYSE: BMY). The program will evaluate the safety and efficacy of Intensity's lead product INT230-6, an investigational, novel and potent anti-cancer drug designed to directly kill cancer cells through intratumoral injection and improve immune cell recognition of cancer, when dosed in combination with Bristol Myers Squibb's Cytotoxic T Lymphocyte-Associated Antigen 4 (CTLA-4) immune checkpoint inhibitor Yervoy® (ipilimumab). The combination will be evaluated in patients with breast cancer, liver cancer and advanced sarcoma in a series of new cohorts within IT-01, Intensity's ongoing Phase 1/2 clinical trial. Intensity will sponsor and conduct the clinical trial and Bristol Myers Squibb will supply Yervoy for use in the study.

"We are pleased to share that Intensity has now partnered with Merck (previously announced on June 25th 2019) and BMS, the two leaders in the cancer immunotherapy space" said Ian B. Walters, MD, CEO of Portage and Chief Medical Officer of Intensity. Recently (March 14, 2020) Intensity also announced favorable safety from the first cohort of the Keynote A10 study (pembrolizumab/anti-PD1 plus Intensity's INT230-6). Intensity is launching into seven phase 2 programs evaluating high unmet medical need tumors types such as colorectal, pancreatic, squamous cell, bile duct, sarcoma, liver and breast cancers.

The full release can be found at: hxxps://intensitytherapeutics.com/media/#media-group-press-releases

So working with both Merck and BMS!

[the stigologist] 06/3/2020 00:58

it's illiquid and on an OTC exchange. Price can't be taken seriously.

Intensity have been tweeting again recently though

[bscuit] 06/3/2020 00:36

P on the move? Closed up 15% @.15

[the stigologist] 25/1/2020 10:58

I'm sure we will.

[dexdringle] 25/1/2020 10:46

Will also increase the value of the Portage shares retained by the old (now delisted) Salvarx. I wonder whether we will ever get to extract our value from that?

[the stigologist] 25/1/2020 10:38

Hearing excited chatter re Portage Biotech and Nasdaq listing

[bscuit] 03/1/2020 19:16

OTC price today $0.12 meaning unless I am wrong for each SAlV share 18 Portage shares x .12 divided by 1.31 (US$/£ exchange rate) or amI missing something?

[the stigologist] 03/1/2020 14:36

FFWD released Portage news as RNS

Includes this bit

"As we move forward, we expect to announce news on subsequent milestones, as research has been progressing on all of our projects. It is our intent to focus the Company on projects that boost the immune system to combat cancer.

(WE ENCOURAGE YOU TO VISIT THE REDESIGNED WEBSITE FOR MORE DETAILS ON THE DEVELOPMENT PROGRAMS AND INDIVIDUALS THAT ARE WORKING TO BRING THESE DISCOVERIES TO CANCER PATIENTS WORLDWIDE: WWW.PORTAGEBIOTECH.COM)"

[the stigologist] 01/1/2020 23:57

Company Operations Update

"We are pleased to report several significant achievements since 2018 which, while resulting in our delay of filing of financial statements, have strengthened the position of Portage and its subsidiaries," said Ian Walters, MD, CEO of Portage. "The combined pipeline from our portfolio companies comprises one of the richest in oncology today. We're pleased to continue to support the work of our companies while identifying additional, new scientific and business development opportunities."

"This past year, we completed several substantial acquisitions and investments, including the purchase of Intensity Holdings, as well as making significant financial investments in Stimunity and iOx Therapeutics," continued Dr. Walters. "In addition, clinical and regulatory progress was highlighted by Intensity's receipt of FDA Fast Track designation for its lead compound, and entry into a research collaboration with Merck. We are confident this collaboration will further the development of new potential treatments for patients with advanced solid tumors. We look forward to continuing our mission of providing funding, business and clinical counsel, and shared services to enable efficient, commercially-informed development of best-in-class therapies."

[the stigologist] 31/12/2019 12:46

Don't see the point of the RTO if we're delisted ? I guess the readmission process should be pretty straightforward and less costly than an IPO

Even if it remains private they can still divest cash and shares to shareholders.

Not too worried it's not a distressed debt situation just sloppy and tardy

[dexdringle] 31/12/2019 11:53

So what happens to Salvarx shares / shareholders? Presumably we become a private limited company?

[the stigologist] 31/12/2019 11:09

As noted in the Company's interim results for the six months ended 30 June 2019, the Company has been evaluating a number of potential acquisition opportunities. The Company is now pleased to announce that it is in advanced discussions with an acquisition target which is a leader in the field of oral immune therapies. Should this proposed acquisition proceed, the Board of SalvaRx anticipates making a further announcement early in the new year, setting out full details of the transaction.

Despite efforts to conclude a reverse takeover before the cancellation date, it will not be possible to conclude the proposed transaction before 10 January 2020. On this basis, the cancellation of the admission to trading of the Ordinary Shares on AIM is expected to take effect from 7.00 a.m. on 10 January 2020.

[dexdringle] 31/12/2019 10:32

Notification received that these will be de-listed from AIM on 10th January.

So much for them becoming a 'cash shell' ?

Is anyone in here still holding these ??

[dexdringle] 22/8/2019 10:38

Where did everyone go ?

Salvx and Portage are now suspended (for different reasons). On the face of it, this isn't exactly encouraging. At best it is poor planning and organisation - never desirable.

[dexdringle] 08/8/2019 08:32

Great. My prediction from 9th July seems to be coming true as Portage are now in the $hit for not filing results on time. There can be only one reason for that - and you can bet your life that it isn't that the numbers are so fantastic they need to be double checked before release.....

Is there a Portage Biotech forum somewhere on the interweb ?